Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Pearl Toh, 11 Oct 2017
Clinical practice is an art guided by good science, and clinical practice guideline (CPG) is meant to guide in integrating the art and science of clinical practice for the long-term benefits of patients, said Dr Abdul Rashid Abdul Rahman, a consultant cardiovascular physician at An-Nur Specialist Hospital in Bangi, Malaysia, during the 13th Asian-Pacific Congress of Hypertension (APCH) held in Singapore.
Dr. James Salisi, 01 Jul 2014

The recent spike in the number of new cases of human immunodeficiency virus (HIV) infection in the Philippines means that clinicians and pharmacists alike may need to increase their awareness and competency in prescribing and monitoring HIV treatment. Although taught in medical and pharmacy schools, the scarcity in exposure to clinical cases before highlights the need to for physicians and pharmacist to review HIV pharmacotherapy in order to cater to the increasing HIV patient population.

01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 

Ranibizumab yields similar visual acuity gains with or without laser in BRVO patients

08 Sep 2017

Use of laser in addition to ranibizumab in the treatment of patients with branch retinal vein occlusion (BRVO) does not result in better functional outcomes or lower treatment need, according to the results of the BRIGHTER study.

The phase IIIB, open-label trial randomly assigned 455 adult patients with visual impairment due to macular oedema secondary to BRVO to groups receiving ranibizumab 0.5 mg (n=183), ranibizumab 0.5 mg with laser (n=180) or laser (with optional ranibizumab 0.5 mg after month 6; n=92). Mean (and mean average) change in best-corrected visual acuity (BCVA) and central subfield thickness (CSFT) were the main outcome measures.

The trial consisted of two treatment periods, with the first period covering day 1 to month 6 and the second period covering months 6 to 23. After initial receipt of three monthly injections, patients on ranibizumab with or without laser received visual acuity (VA) stabilization criteria-driven pro re nata (PRN) treatment. On the other hand, patients assigned to the laser monotherapy arm were given ranibizumab from month 6 at the discretion of the investigators.

Of the patients, 380 (83.5 percent) completed the study. BCVA outcomes were superior in the two ranibizumab arms versus laser (monotherapy and combined with ranibizumab from month 6; 17.3 and 15.5 vs 11.6 letters; p<0.0001).

While the ranibizumab with laser arm was noninferior to ranibizumab monotherapy arm (mean average BCVA change, 15.4 vs 15.0 letters; p<0.0001), the addition of laser did not reduce the number of ranibizumab injections (mean injections, 11.4 vs 11.3; p=0.4259).

Ranibizumab with laser resulted in a greater reduction in CSFT over 24 months from baseline compared with ranibizumab monotherapy (ranibizumab monotherapy, −224.7 μm; ranibizumab with laser, −248.9 μm; laser [monotherapy and combined with ranibizumab from month 6], −197.5 μm).

Macular ischaemia did not influence BCVA outcome or treatment frequency. Neovascular glaucoma or iris neovascularization did not occur with any of the treatment arms, and no new safety signals were identified.

Despite the presence of limitations, the BRIGHTER study results confirm the long-term efficacy and safety profile of PRN dosing driven by individualized VA stabilization criteria using ranibizumab 0.5 mg in patients with BRVO, researchers said, adding that the safety results add to the well-established safety profile of the drug.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Pearl Toh, 11 Oct 2017
Clinical practice is an art guided by good science, and clinical practice guideline (CPG) is meant to guide in integrating the art and science of clinical practice for the long-term benefits of patients, said Dr Abdul Rashid Abdul Rahman, a consultant cardiovascular physician at An-Nur Specialist Hospital in Bangi, Malaysia, during the 13th Asian-Pacific Congress of Hypertension (APCH) held in Singapore.
Dr. James Salisi, 01 Jul 2014

The recent spike in the number of new cases of human immunodeficiency virus (HIV) infection in the Philippines means that clinicians and pharmacists alike may need to increase their awareness and competency in prescribing and monitoring HIV treatment. Although taught in medical and pharmacy schools, the scarcity in exposure to clinical cases before highlights the need to for physicians and pharmacist to review HIV pharmacotherapy in order to cater to the increasing HIV patient population.

01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute.